Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals

Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals

Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform

TORONTO, July 20, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has entered into an Intellectual Property Licensing & Royalty Agreement (“IPLRA”) with Ei.Ventures, Inc. (“Ei.”) to develop and commercialize functional fungi-based products.

“Over the past six years our team established a scientific platform that has led to the commercialization of several products across international commercial channels in the regulated cannabis industry. As a part of our continued growth, we are thrilled to be entering into this agreement where our goal will be to demonstrate our scientific capabilities across alternative natural products and developing new fungi-based functional products. We look forward to working towards developing the new products in the nutraceutical area in a standardized and evidence-based way, as we have with our initial cannabinoid-based products.” stated Aras Azadian, CEO of Avicanna.

The initial focus of the research and development efforts will be on functional, apoptogenic, fungi-based formulations in the form of consumer friendly and single dosed products. The new product development efforts are to be led by Avicanna’s R&D team, leveraging the company’s existing scientific platform and proprietary delivery systems to develop appropriately dosed and synergistic formulations.

“We are excited to enter into this agreement with Avicanna to develop and commercialize the Psilly™ brand of products, starting with functional mushroom blends, gummies and chocolates, and which relationship can potentially evolve to botanical psychedelic pharmaceutical products” states David Nikzad, CEO of Ei. Nikzad continues, “we believe in the Avicanna team and their mission to develop advanced and proprietary plant-based formulations, and we will bring our blockchain, Web3 and Metaverse assets to scale and support the success of the products developed under our agreement.”

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Click to watch Avicanna’s Corporate Video 2022

SOURCE Avicanna Inc.

About Ei.Ventures, Inc.

Ei.Ventures Inc. is an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology. Ei is leveraging blockchain, emerging technologies and the Metaverse to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. It is the goal of Ei to utilize the development of these technologies, to create a safe, efficient, and secure way to provide telehealth services in general and specifically to the psychoactive therapeutics. Additional information on Ei can be found on the Ei’s website at: https://www.ei.ventures.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedInTwitterFacebook or Instagram.

The Company posts updates through videos from the official Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2022 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

A photo accompanying this announcement is available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d10bb5-5453-4115-acc9-ff4385d04cbd

RE+PLAY ANNOUNCES THE NBPA AS AN OFFICIAL PARTNER

RE+PLAY ANNOUNCES THE NBPA AS AN OFFICIAL PARTNER

The performance-based wellness and recovery line created by Harrington Wellness will partner with the NBPA to bring topicals and technologically advanced products to the masses via Amazon and Walmart

NEW YORK, NY, July 12, 2022 – Re+Play, the performance-based wellness and recovery line of Harrington Wellness, is pleased to announce a new multi-year partnership with The National Basketball Players Association (NBPA), designating Re+Play as an official partner. The equity partnership will allow Re+Play to bring the latest in recovery promoting products and technology to athletes of all levels. 

The landmark multi-year product development plan brings recovery-promoting technology to the masses, with offerings from topicals, kinesiology tape, and massage guns, among other naturally infused-pain products.

“Re+Play’s partnership with the NBPA will provide consumers with a wealth of trusted, technology-driven products, to help them recover like a pro,” said Al Harrington, CEO of Harrington Wellness and former NBPA member. “As we move into the next phase of the Re+Play brand with our strategic partners at Amazon, the NBPA, and Walmart, we are excited to once again reimagine how we help athletes of all levels recover from pain with CBD and other innovative technology.”

“Harrington Wellness is a leader and innovator in recovery products for consumers and we are excited to join them in this landmark equity partnership to support and promote their Re+Play line of products,” said Que Gaskins, Interim President of THINK450. The first product release from this new partnership is a line of proprietarily formulated recovery creams — developed in partnership with Avicanna, a biopharmaceutical company focused on the development of plant-derived cannabinoid based products.

“It was important that we developed a product that was clearly evidence-based and targeted at improving muscle recovery,” stated Dr. Sanford Kunkel, Chief Medical Officer, Harrington Wellness & Re+Play. “Through our partnership with Avicanna—we were able to develop our line at its R&D headquarters in the Johnson & Johnson Innovation Center, JLABS, giving us a significant competitive product advantage.’’

This new Re+Play product can be purchased at www.replayrecovery.com and will soon be available through the Replay Recovery Store at Amazon.com and Walmart.com.

“By partnering with Amazon and Walmart, two leading retailers, we can continue our mission to bring high-quality recovery-promoting products to the everyday customer in places that they are looking for them,” said Erin Hackney, President of Harrington Wellness. “Gaining access to a new set of pain relief-seeking consumers allows Re+Play the opportunity to further establish itself as a trusted brand in the recovery category.

###

About Harrington Wellness Harrington Wellness’ Re+Playis the performance-based recovery brand founded by NBA Veteran Al Harrington, renowned trainer Joe Abunasser and Dr. Sanford Kunkel, the team physician for both the Indiana Pacers and the USA national basketball team.

Built with the fundamentals and combined knowledge of scientists, athletes, doctors, and certified athletic trainers, the line uses the latest technology and delivers the powerful benefits of CBD through advanced formulations that have undergone extensive research and development to meet the quality and consistency standards that athletes, physicians, and the everyday consumer can be confident in.

About the NBPA
The National Basketball Players Association is the union for current professional basketball players in the National Basketball Association (NBA). Established in 1954, the NBPA’s mission is to protect and support the rights and talents of our players, magnify the power of their collective will, and amplify their voices as leaders who will transcend sport and society globally.

The NBPA advocates on behalf of the best interests of all NBA players, including through the negotiation of collective bargaining agreements, the filing of grievances on behalf of the players, and counseling players on benefits, educational and post-NBA career opportunities. Business opportunities are generated by THINK450, the subsidiary of the NBPA charged with managing the players’ group licensing rights. 

Dedicated to preserving the legacy of its members, the NBPA Foundation provides support and assistance to persons, communities, and organizations around the world that seek to improve the lives of those in need. 

About THINK450
THINK450 is the innovation and partnership engine of the NBPA, dedicated to uncovering shared interests between the 450 players and leading brands to build more engaging partnerships. Together with its partners, THINK450 creates original ideas that engage fans, stir them to action, and earn brands the right to participate in cultural conversations.

For more information, visit THINK450.com.

Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union

Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union

The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio

Initial portfolio launch is planned for Germany, Austria, and Switzerland in Q3 2022

TORONTO, July 07, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has completed its first commercial export of its evidence-based derma-cosmetic line Pura H&W (“Pura” or “Pura Health & Wellness”) into the European Market as a part of its supply and distribution agreement with Bio-Gate AG (“Bio-Gate”).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bab76054-b480-4a1c-9d7a-0b8d3813b05b

Avicanna’s evidence-based derma-cosmetics portfolio has now been successfully imported into Germany where Bio-Gate prepare to launch this summer. The portfolio of products will initially be available online at http://www.purahw.com and then further expanded into other online, retail and pharmacy channels across Germany, Austria, and Switzerland during 2022.

“We are pleased to be entering the European market with our first line of branded products and to be doing so in collaboration with Bio-Gate. Both teams are excited about the launch of the skincare portfolio in the coming months and are happy to see the Pura Health and Wellness brand establish a new European foothold,” commented Jens Kramer, VP of European Operations at Avicanna.

To its knowledge, Avicanna carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Pura H&W

Pura Health & Wellness (Pura H&W) is Avicanna’s derma-cosmetic line which utilizes a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials. The products are now commercial under Pura H&W or Pura Earth in Canada, Colombia, Ecuador, the U.S.

The Pura H&W formulations have been developed and optimized to deliver purified, THC-free CBD in synergistic combinations with other natural ingredients known to provide specific functional benefits in skincare. CBD has been shown to promote skin health by inducing antioxidant, anti-inflammatory, and anti-apoptotic responses that could be beneficial for a variety of dermatological conditions such as eczema or atopic dermatitis. In addition, CBD can down-regulate the activity of cells that are critical in the production of skin oils and therefore may dampen the production in acne-prone skin.

About Bio-Gate AG

Bio-Gate AG is a health technology company and a leading provider of innovative technologies and products for health, infection control and hygiene that can make living together safer and healthier, and improve the well-being of each individual. Bio-Gate specializes in providing materials and surfaces with antiviral, antimicrobial or biologically active properties. Bio-Gate AG enhances materials and products, particularly in the field of medical technology, for example in the coating of implants or wound dressings. In addition, Bio-Gate technologies are used in dermatological active cosmetics and wound care products, as well as consumer and industrial products.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Click to watch Avicanna’s Corporate Video 2022

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedInTwitterFacebook or Instagram.

The Company posts updates through videos from the official Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2022 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.